AbCellera Biologics Inc. (ABCL) is poised for growth with new molecules advancing into clinical trials. CEO Carl Hansen sees potential in treating autoimmune disorders, cancers, and infectious diseases. Despite previous setbacks, recent progress suggests transformative potential.